Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Emerg Infect Dis ; 26(11): 2709-2712, 2020 11.
Article in English | MEDLINE | ID: mdl-32917293

ABSTRACT

Coronavirus disease has disrupted tuberculosis services globally. Data from 33 centers in 16 countries on 5 continents showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019. Resources are needed to ensure tuberculosis care continuity during the pandemic.


Subject(s)
Continuity of Patient Care/trends , Coronavirus Infections/epidemiology , Facilities and Services Utilization/trends , Global Health/trends , Pneumonia, Viral/epidemiology , Tuberculosis/therapy , Betacoronavirus , COVID-19 , Humans , Pandemics , SARS-CoV-2 , Tuberculosis/epidemiology
2.
New Microbiol ; 43(3): 139-143, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32656568

ABSTRACT

Inflammatory Bowel Diseases (IBD) and intestinal tuberculosis (ITB) frequently share similar clinical, radiological, endoscopic and histologic features. The misdiagnosis of IBD can lead to worsening of ITB course, eventually with dissemination of Mycobacterium tuberculosis (MTB) due to immunosuppressive treatment. We herein report a challenging diagnosis of ITB, progressed from localized to disseminated, in a pregnant woman previously misdiagnosed with Crohn' disease (CD) on prolonged steroid treatment. Furthermore, we focus on three main issues: 1) the need for tuberculosis (TB) screening in pregnant women and in patients coming from TB endemic countries; 2) the effect of prolonged steroid treatment in misdiagnosed TB, particularly on its histological pattern; 3) the optimum clinical management of ITB.


Subject(s)
Crohn Disease , Mycobacterium tuberculosis , Tuberculosis, Gastrointestinal , Crohn Disease/diagnosis , Crohn Disease/drug therapy , Diagnosis, Differential , Diagnostic Errors , Female , Humans , Pregnancy , Tuberculosis, Gastrointestinal/diagnosis , Tuberculosis, Gastrointestinal/drug therapy
4.
Eur Respir J ; 56(1)2020 07.
Article in English | MEDLINE | ID: mdl-32457198
5.
Eur Respir J ; 54(4)2019 10.
Article in English | MEDLINE | ID: mdl-31413161

ABSTRACT

In countries of the European Union, tuberculosis (TB) mainly affects marginalised people, including asylum seekers. Migratory flows from high-incidence countries to Italy have increased up to 2017, posing challenges to the national health system. This study sought to assess TB and latent TB infection (LTBI) prevalence among asylum seekers in Milan during the biennium 2016-2017 and to evaluate interventions in place.A two-level active surveillance and screening system was developed for both TB and LTBI. Asylum seekers underwent an initial screening with a tuberculin skin test (TST) and a questionnaire at the receiving sites. At the Regional TB Reference Centre, those with a positive result underwent chest radiography. People aged <35 years with negative chest radiography results underwent further testing by interferon-γ release assay. If results of the assay were positive, LTBI treatment was offered. TB and LTBI prevalence were compared with literature data.A total of 5324 asylum seekers, mostly young (10-39 years; 98%), male (84%) and from sub-Saharan Africa (69%), were enrolled in the study. 69 active TB cases were diagnosed and 863 LTBI-positive individuals were detected. TB prevalence was high (1236 per 100 000 population) and LTBI prevalence was 28%. Despite losses (41%) during the transition from initial screening sites and the diagnostic centre, a good TB cure rate (84%) and optimal LTBI treatment completion (94%) were achieved.Our study shows that TB incidence is high among asylum seekers in Milan and that well-coordinated screening measures are critical for early diagnosis and treatment. It also proves that rolling out successful at-scale interventions for both prophylaxis and disease management is feasible.


Subject(s)
Latent Tuberculosis/epidemiology , Refugees/statistics & numerical data , Tuberculosis, Lymph Node/epidemiology , Tuberculosis, Pulmonary/epidemiology , Adolescent , Adult , Africa, Eastern/ethnology , Africa, Northern/ethnology , Africa, Western/ethnology , Antitubercular Agents/therapeutic use , Asia, Western/ethnology , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Interferon-gamma Release Tests , Italy/epidemiology , Latent Tuberculosis/diagnosis , Latent Tuberculosis/drug therapy , Male , Mass Screening , Prevalence , Radiography, Thoracic , Treatment Outcome , Tuberculin Test , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Tuberculosis/epidemiology , Tuberculosis, Lymph Node/diagnosis , Tuberculosis, Lymph Node/drug therapy , Tuberculosis, Multidrug-Resistant/diagnosis , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/drug therapy , Young Adult
6.
J Clin Med ; 9(1)2019 Dec 31.
Article in English | MEDLINE | ID: mdl-31906078

ABSTRACT

To tackle the tuberculosis (TB) epidemic, in 2014 the World Health Organization launched the End TB Strategy, which includes action to prevent latent TB infection (LTBI) reactivation. Available preventive treatments (PT) are based on either isoniazid (INH) alone or rifampicin (RIF)-containing regimens. This study aims to assess and compare PT completion rates, the occurrence of adverse events, and the time of dropout among those receiving INH-alone or RIF-containing regimens at Villa Marelli Institute, Milan, Italy, covering the period from 1992 to 2018. A total of 19670 subjects, belonging to various risk groups-mainly young (median age of 29 years), foreign-born (73.3%), and males (58.8%)-with presumed LTBI were prescribed PT (79.3% INH-alone and 20.7% RIF-containing regimens). The treatment completion rate was 79.4% on average, with higher rates among those receiving RIF-containing regimens (85.6%) compared to those that were prescribed INH-alone (77.8%) (p < 0.0001). Notably, some of the high-risk groups for progression of LTBI were more likely to complete PT from RIF-containing regimens. These groups included recent TB contact (89.9%, p < 0.0001), healthcare workers (93.5%, p < 0.0001), and homeless people (76.6%, p < 0.0001). Irrespectively of the chosen PT regimen, most of the dropouts occurred between the start of the treatment and the first follow-up visit (14.3%, 15.2% for those on INH-alone vs. 11.1% for those on RIF-containing regimens). Further shortening of the PT regimen is therefore an aim to ensure adherence, even though it might need further efforts to enhance the patient's attitude towards starting and carrying out PT.

SELECTION OF CITATIONS
SEARCH DETAIL
...